Therapy of endocrine disease: steroidogenesis enzyme inhibitors in Cushing's syndrome.

@article{Daniel2015TherapyOE,
  title={Therapy of endocrine disease: steroidogenesis enzyme inhibitors in Cushing's syndrome.},
  author={Eleni Daniel and John Newell-Price},
  journal={European journal of endocrinology},
  year={2015},
  volume={172 6},
  pages={R263-80}
}
Steroidogenesis enzyme inhibitors are the mainstay of medical therapy in Cushing's syndrome (CS). Ketoconazole (KTZ) and metyrapone are the most commonly used agents. Although there is considerable experience of their use in individual specialist centres, these drugs have not been rigorously tested in prospective clinical trials. Clinicians face uncertainties and concerns with respect to the safety profile of these agents, and best means to monitor effect. We review steroidogenesis inhibitors… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 161 references

Effectiveness of metyrapone in 195 patients with Cushing’s syndrome

E Daniel, S Aylwin, +7 authors S Rajeev
Endocrine Abstracts • 2014

Ketoconazole in Cushing's disease: is it worth a try?

The Journal of clinical endocrinology and metabolism • 2014

Normalization of urinary cortisol with the potent 11b-hydroxylase inhibitor LCI699 in patients with Cushing’s disease: 22-week, multicentre, open-label study

JY Beverly Biller, A Hamrahian, +7 authors A Hilliard
Endocrine Abstracts 2014 • 2014

Con: etomidate--the ideal induction agent for a cardiac anesthetic?

Journal of cardiothoracic and vascular anesthesia • 2013

Similar Papers

Loading similar papers…